Lakefront Biotherapeutics (LKFT.AS)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 478 | 485 | 505 | 240 | 276 | 1,112 | 1,044 | - |
| Operating profit | €m | 470 | 380 | ||||||
| Net profit | €m | -311 | -125 | -218 | 212 | 74 | 321 | 489 | - |
| EPS reported | € | 4.87 | 7.41 | ||||||
| Operating cashflow per share | € | -2.99 | -4.44 | ||||||
| Capex per share | € | 0.21 | 0.13 | ||||||
| FCF per share | € | -3.20 | -4.57 | ||||||
| Free cash flow | €m | -211 | -301 | ||||||
| Net debt | €m | -2,998 | -2,982 | ||||||
| Book value equity | €m | 3,236 | 3,253 | ||||||
| Book value per share | € | 49.11 | 47.14 | ||||||
| Number of shares | m | 65.89 | 69.01 | ||||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 5.75 | 3.32 | ||||||
| P/B LTM | x | 0.57 | 0.57 | ||||||
| P/S LTM | x | 1.66 | 1.77 | ||||||
| P/FCF LTM | x | -8.76 | -6.13 | ||||||
| EV/EBITDA LTM | x | 3.38 | 5.36 | ||||||
| EV/Sales LTM | x | 1.59 | 1.46 | ||||||
| Earnings Yield LTM | % | +17.39% | +30.12% | ||||||
| FCF Yield | % | -11.42% | -16.32% | ||||||
| Quality | |||||||||
| ROE | % | +9.92% | +16.88% | ||||||
| ROIC | % | +14.43% | +11.61% | ||||||
| Operating margin | % | +42.23% | +36.43% | ||||||
| Gross margin | % | +92.66% | +98.01% | ||||||
| FCF/Sales | % | -18.94% | -28.85% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +334.82% | +561.61% | ||||||
| Sales Growth YoY | % | +303.50% | +278.65% | ||||||
| Net Income Growth YoY | % | +333.15% | +559.78% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -30.47 | -46.79 | ||||||
| Net Debt/EBITDA | x | -0.16 | -0.18 | ||||||
| EBIT/Net interest | x | 279.56 | 171.26 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -0.93 | -0.92 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free